Ads
related to: postpartum anxiety medication
Search results
Results from the WOW.Com Content Network
An estimated 1 in 5 women struggle with perinatal mood and anxiety disorders after birth. But the future of postpartum mental health care is getting brighter.
The US Food and Drug Administration has approved the medication zuranolone for the treatment of major depressive disorder and severe postpartum depression – making it the first FDA-approved oral ...
Postpartum depression (PPD), also called perinatal depression, is a mood disorder which may be experienced by pregnant or postpartum individuals. [3] Symptoms may include extreme sadness, low energy, anxiety, crying episodes, irritability, and changes in sleeping or eating patterns. [1]
It is a difficult time for those who suffer from this condition. Postpartum depression could be short-lived but it can also last up to two years after the mother gives birth. Postpartum depression has the potential to bring on more mental conditions for new mothers such as obsessive-compulsive disorder and/or anxiety.
Sep. 7—A new drug treating postpartum depression was approved earlier this month by the Food and Drug Administration — possibly filling a gap in care, depending on the drug's accessibility to ...
Allergic reactions, neurological disorders, and cardiovascular conditions should always be considered, but especially so if treatment is long-term. OT can modify heart rates and cause excessive fluid intake (antidiuretic effect). Intravenous infusion (IV) of oxytocin is often used to induce labor and enhance milk lactation during postpartum care.
Ads
related to: postpartum anxiety medication